A Case of Central Serous Chorioretinopathy Associated With Retinal Detachment Improved by Intravitreal Bevacizumab Injection

Bum Ho Sin; Jae Keun Jeoung; Sung Pyo Park

doi:10.3341/jkos.2010.51.10.1419

Journal List > J Korean Ophthalmol Soc > v.51(10) > 1008675

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Sin, Jeoung, and Park: A Case of Central Serous Chorioretinopathy Associated With Retinal Detachment Improved by Intravitreal Bevacizumab Injection

Original Article

J Korean Ophthalmol Soc 2010;51(10):1419-1422.

Published online: 7 September 2010

DOI: https://doi.org/10.3341/jkos.2010.51.10.1419

A Case of Central Serous Chorioretinopathy Associated With Retinal Detachment Improved by Intravitreal Bevacizumab Injection

Bum Ho Sin, MD, Jae Keun Jeoung, MD, Sung Pyo Park, MD, PhD

Department of Ophthalmology, Kang dong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea

Address reprint requests to Sung Pyo Park, MD, PhD Department of Ophthalmology, Kangdong Sacred Heart Hospital #445 Gil-dong, Gangdong-gu, Seoul 134-701, Korea Tel: 82-2-2224-2274, Fax: 82-2-470-2088, E-mail: sungpyo@hananet.net

Received 8 April 2010 Accepted 30 June 2010

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To report a case of chronic central serous chorioretinopathy treated with an intravitreal injection of 2.5 mg of bevacizumab.

Case summary

A 38-year-old male complained of visual disturbance in the right eye. He had a history of central serous chorioretinopathy which improved without treatment. Since the patient did not feel any ocular discomfort, he did not visit our clinic for approximately 11 months. At the time of presentation, fundus examination revealed exudative retinal detachment involving the macular area. Additionally, fluorescein angiography revealed multiple early phase hyperfluorescent lesions. Neurosensory detachment around the macula and increased central macular thickness were also observed using optical coherence tomography. Under the diagnosis of chronic central serous chorioretinoapthy, the patient was treated with 2.5 mg of intravitreal bevacizumab. Visual acuity improved two months after treatment, with improvement in both neurosensory retinal detachment and fluorescein leakage. No changes were observed at the six-month follow-up.

Keywords: Bevacizumab, Chronic central serous chorioretinopathy (CSC)

References

1. Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol. 1986; 224:321–4.

2. Gass JD. Pathogenesis of disciform detachment of the aberrations. Am J Ophthalmol. 1967; 63(Suppl):1–139.

3. Lafaut BA, Salati C, Priem H, De Laey JJ. Indocyanine green angiographic is of value for the diagnosis of chronic serous chorioretinopathy in elderly patients. Graefes Arch Clin Exp Ophthalmol. 1998; 236:513–21.

4. Piccolino FC, Borgia L, Zinicola E, Zingirian M. Indocyanine green angiographic findings in central serous chorioretinopathy. Eye. 1995; 9:324–32.

5. Schaal KB, Hoeh AE, Scheuerle A, et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2009; 19:613–7.

6. Artunay O, Yuzbasioglu E, Rasier R, et al. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: A prospective, controlled clinical study. Curr Eye Res. 2010; 35:91–8.

7. Seong HK, Bae JH, Kim ES, et al. Intravitreal Bevacizumab to treat acute central serous chorioretinopathy: Short-term effect Ophthalmologica. 2009; 223:343–7.

8. Torres-Soriano ME, García-Aguirre G, Kon-Jara V, et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (Case report). Graefes Arch Clin Exp Ophthalmol. 2008; 246:1235–9.

9. Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina. 2010; 30:100–6.

10. Kim M, Chung M. The result of photodynamic therapy in chronic central serous chorioretinopathy. J Korean Ophthalmol Soc. 2009; 50:1035–45.

11. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol. 1994; 112:1057–62.

12. Azad RV, Rani A, Pal N, et al. Current and future role of photo-dynamuc therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2005; 139:393–4.

13. Colucciello M. Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy. Retina. 2006; 26:239–42.

14. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007; 48:2814–23.

15. Amselem L, Cervera E, Diaz-Llopis M, et al. Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up. Eye. 2007; 21:566–7.

Figure 1.

Fundus photographs, fluorescein angiographs (FAG) and optical coherence tomographs (OCT) of the patient's right eye with CSC. Two months after observation without treatment (A, B, C), fundus photograph reveals a yellowish membranous lesion around the macular area (A). FAG reveals hyperfluorescent lesion around the macular area (B). Neurosensory retinal detachment is observed by OCT (C). On the day of severely decreased visual acuity (D, E, F). Fundus photograph shows exudative retinal detachment involving the macular area (D), and FAG reveals increased number and size of the hyperfluorescent lesion (E), Intraretinal edema was observed by OCT (F). Two months after intravitreal 2.5-mg bevacizumab injection (G, H, I). Fundus photograph shows resolution of the retinal detachment. (G) and hyperfluorescent lesion improved on FAG (H). OCT reveals complete resolution of SRF (I).

Figure 2.

Fundus photograph on the day of severely decreased visual acuity. Note an elevated serous lesion involving the macula (black arrow lined) (A). Two months after intravitreal 2.5-mg bevacizumab injection, resolution of the retinal detachment and subretinal fibrous band are observed (B).

TOOLS

Similar articles